Brand: iMatrix™ by Matrixome®
Purchase product: USA Store
|Product Code||Pack Size||Price in
|Prices in UK, Europe,
Middle East & Africa
|NP892-061||175 μg × 2 tubes||USD $ 621.00||GBP £ 557.41||EUR € 632.67|
|NP892-062||175 μg × 6 tubes||USD $ 1,553.00||GBP £ 1,393.52||EUR € 1,581.69|
Prices do not include shipping and handling charges.
iMatrix-221 is a xeno-free, recombinant Laminin-221 E8 Fragment expressed in CHO-S cells. Laminins of the α2-isoform are commonly found in the basal lamina of striated muscle and the predominant form found in adult human heart tissue.
iMatrix-221's features make it an ideal matrix for some cell culture applications:
iMatrix-221 is a highly purified and refined product of human recombinant laminin-221 (E8 fragment) expressed by CHO-S cells. Laminin-221 is found predominantly in the basal lamina of striated muscle tissues. Expression deficiencies are implicated in muscular dystophy and cardiomyopathies.1
Laminins of the α-2 type are also a predomiant form found in the human adult heart tissue.2 Cultivation of iPSC-drived cardiomyocytes on iMatrix-221 has been demonstrated to maintain strong contractility in attached monolayer culture.3
Product Name: iMatrix-221 Cardiac and Myoblast Cell Culture Substrate
Molecular Weight: 150 kDa
Purity: > 95 % pure
Formulation: Purified Laminin-221 E8 proteolytic fragment
Storage and Stability: Store at 4 °C and protect from light exposure. Stable for 2 years from manufacturing date.
Quality Control: Activity: Kd for integrin binding
Notice To Purchaser: REPROCELL is a licensed distributor of Matrixome cell culture substrates to the global market.
Recommended Usage: iMatrix-221 is suitable for use as a substrate for culture of various myoblast cell types, but most notably for cardiomyocytes.
Concentration: 500 µg/mL
Source: CHO-S cell expression
Manufacturer: Matrixome Corporation (Japan)
Stem Cells / 13 September 2021
Clinical Capabilities / 9 September 2021
15 September 2021
2 September 2021
18 August 2021
© 2021 REPROCELL Inc. All rights reserved.